2022
DOI: 10.1007/s13139-021-00728-0
|View full text |Cite
|
Sign up to set email alerts
|

KSNM60 in Nuclear Endocrinology: from the Beginning to the Future

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 65 publications
0
1
0
Order By: Relevance
“…The ability to quantify the disease at a molecular level, tumor hypoxia, and bone metastases may help assess the global inhibitory effect of such multi-targeted therapeutic approaches. Notwithstanding, there is a lack of personalized radiotracers in PET-CT radiotracers, which presents a major limitation to the molecular imaging role in personalized medicine [ 11 , 48 , 72 , 95 , 96 , 97 ].…”
Section: Positron Emission Tomography (Pet)mentioning
confidence: 99%
“…The ability to quantify the disease at a molecular level, tumor hypoxia, and bone metastases may help assess the global inhibitory effect of such multi-targeted therapeutic approaches. Notwithstanding, there is a lack of personalized radiotracers in PET-CT radiotracers, which presents a major limitation to the molecular imaging role in personalized medicine [ 11 , 48 , 72 , 95 , 96 , 97 ].…”
Section: Positron Emission Tomography (Pet)mentioning
confidence: 99%